Thermimage Completes Extensive Market Study

September 9, 2008 (Salt Lake City, Utah) – Thermimage Inc recently completely an extensive market study to determine incidence rates of pediatric Vesicoureteral Reflux and the potential market for the company’s product. “The Company’s market research determined that the Thermaflux Scanner™ represents a significant revenue growth opportunity for hospitals, group practices, and individual doctor’s offices,” said Doug Turnquist, President & CEO of Thermimage. “Currently, diagnosing VUR can only be completed in a hospital. Hospitals will likely increase the number of VUR diagnostic procedures based on the non-invasive nature of the Thermaflux Scanner™. Group practices and individual doctors’ offices currently send children to the hospital for a VCUG or simply guess that the child suffers from VUR and treat blindly. A Thermaflux Scanner™ in these offices will eliminate guesswork or a hospital referral for many suspected cases of VUR while also driving revenue to the physician.”

Thermimage Inc was founded in February 2007 to commercialize a non-invasive, painless and less costly way to produce deep-tissue temperature measurements. The device will first be used to diagnose Vesicoureteral Reflux (VUR) in children, a dangerous condition that allows urine to backflow into the kidneys of young children. The current procedure is painful and requires the use of catheters and ionizing radiation, where this new technique will heat the contents of the bladder and then detect any increase in temperature in the kidneys signaling reflux.

image
image
image